More humans die in the intensive care unit from sepsis than from any other cause. Death from sepsis is the culmination of widespread hypoperfusion, cellular hypoxia, and multiple organ failure. A growing body of evidence shows that early therapeutic intervention improves outcome for patients with sepsis. Novel targeted strategies that bolster a strong and durable systemic hemodynamic response have been proven to reduce or even reverse organ dysfunction in patients with sepsis. L-carnitine provides the key elements of a novel therapy to ameliorate the adverse hemodynamic effects of sepsis. The overall goal of this proposal is to investigate L-carnitine as a novel adjunctive treatment of septic shock; specifically to test the clinical efficacy of L-carnitine on reducing organ failure, a critical patient oriented outcome, and provide evidence as to whether stimulation of carbohydrate oxidation creates host resilience to severe sepsis.
|Effective start/end date||6/1/12 → 5/31/16|
- University of Mississippi Medical Center (66100920513-NU//1R011GM103799)
- National Institute of General Medical Sciences (66100920513-NU//1R011GM103799)